The Foundation Dedicated to Discovering a Cure for Neuroendocrine Cancer

Caring for Carcinoid Foundation

Octreotide implant development discontinued

Wednesday, May 4, 2011 - 10:44

In a 2011 10Q Quarterly Report, Endo Pharmaceutcials reported that it is discontinuing development of its Octreotide implant for carcinoid syndrome. This decision was based on research that identified commercial challenges in bringing the product to market.  The Octreotide implant was Endo's only product in development for carcinoid syndrome.  At this time Endo remains committed to development of its Octreotide implant for the treatment of acromegaly.  Information available here.

The Caring for Carcinoid Foundation is dedicated to bringing patients the latest information on carcinoid, pancreatic neuroendocrine, and related neuroendocrine cancers.  Click here for information on treatments, or here for current clinical trials.

The Caring for Carcinoid Foundation acknowledges the challenges in developing treatments for patients with rare diseases.  To learn more about advocacy efforts for patients with carcinoid, pancreatic neuroendocrine, and related neuroendocrine cancers, please click here or here.

Make a Difference Get Involved Today

Sign-up for our e-Newsletter.

E-update Archive

Nancy

Ron's Blog

Read the latest blog from CFCF's Executive Director.

Lauren

Lauren's Blog

Read the latest blog from CFCF's Director of Research.

video

Latest Video

Check out the CFCF video library.

Connect with CFCF online:
FacebookTwitterYouTube

Seal Exchange